Antonella Carambia
Overview
Explore the profile of Antonella Carambia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
822
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kunzmann L, Schoknecht T, Poch T, Henze L, Stein S, Kriz M, et al.
Hepatology
. 2020 Oct;
72(4):1310-1326.
PMID: 33090557
Background And Aims: T cells from patients with primary sclerosing cholangitis (PSC) show a prominent interleukin (IL)-17 response upon stimulation with bacteria or fungi, yet the reasons for this dominant...
12.
Schumacher N, Yan K, Gandrass M, Muller M, Krisp C, Hasler R, et al.
J Hepatol
. 2020 Sep;
74(2):407-418.
PMID: 32987028
Background & Aims: Interleukin (IL)-6 cytokine family members contribute to inflammatory and regenerative processes. Engagement of the signaling receptor subunit gp130 is common to almost all members of the family....
13.
Schuran F, Lommetz C, Steudter A, Ghallab A, Wieschendorf B, Schwinge D, et al.
Cell Mol Gastroenterol Hepatol
. 2020 Sep;
11(2):371-388.
PMID: 32932016
Background & Aims: Acetaminophen (APAP)-induced liver injury is one of the most common causes of acute liver failure, however, a clear definition of sensitizing risk factors is lacking. Here, we...
14.
Herkel J, Carambia A, Lohse A
J Hepatol
. 2020 Jul;
73(2):446-448.
PMID: 32600827
No abstract available.
15.
Glaser F, John C, Engel B, Hoh B, Weidemann S, Dieckhoff J, et al.
J Hepatol
. 2019 Jun;
71(4):783-792.
PMID: 31207266
Background & Aims: T cells are central mediators of liver inflammation and represent potential treatment targets in cholestatic liver disease. Whereas emerging evidence shows that bile acids (BAs) affect T...
16.
Schliffke S, Carambia A, Akyuz N, Thiele B, Herkel J, Binder M
J Neuroimmunol
. 2019 Apr;
332:49-56.
PMID: 30933850
The experimental autoimmune encephalomyelitis (EAE) model is indispensable for autoimmunity research, but model-specific T cell dynamics are sparsely studied. We used next-generation immunosequencing across lymphoid organs, blood and spinal cord...
17.
Carambia A, Herkel J
Semin Immunopathol
. 2017 Nov;
40(2):175-188.
PMID: 29110070
The liver is the central metabolic organ of the organism and is thus constantly exposed to gut-derived dietary and microbial antigens. The liver maintains homoeostatic tolerance to these mostly harmless...
18.
Schwinge D, von Haxthausen F, Quaas A, Carambia A, Otto B, Glaser F, et al.
J Hepatol
. 2016 Dec;
66(4):798-805.
PMID: 27965154
Background & Aims: Reduced numbers of regulatory T cells (Treg) have been reported in patients with primary sclerosing cholangitis (PSC); therefore, Treg expansion might serve as a therapeutic approach. Here,...
19.
Bergmann J, Muller M, Baumann N, Reichert M, Heneweer C, Bolik J, et al.
Hepatology
. 2016 Oct;
65(1):89-103.
PMID: 27770462
Conclusion: IL-6 trans-signaling, and not IL-6 classic signaling, is mandatory for development of hepatocellular carcinogenesis. Therefore, specific inhibition of IL-6 trans-signaling, rather than total inhibition of IL-6 signaling, is sufficient...
20.
Kozik J, Trautmann T, Carambia A, Preti M, Lutgehetmann M, Krech T, et al.
Sci Rep
. 2016 Jun;
6:28556.
PMID: 27328755
TREM1 (Triggering Receptor Expressed on Myeloid Cells 1) is a pro-inflammatory receptor expressed by phagocytes, which can also be released as a soluble molecule (sTREM1). The roles of TREM1 and...